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Abstract  
 
Herpes viruses are double stranded DNA viruses, classified under three sub-
groups; alpha-, beta- (to which human cytomegaloviruses belong), and 
gammaherpesviruses.  
HCMV structure consists of icosahedral capsid encasing 235-kbp genome. The 
capsid is surrounded by the tegument, which is surrounded by the envelope.  pp65 
is a major viral tegument proteins with multiple phosphorylation sits. UL97 is 
also a tegument protein and encodes the only viral kinase, which is a 
serine/threonine protein kinase that plays a role in phosphorylation events of viral 
and cellular proteins. The viral envelop contains a large number of virus-encoded 
glycoproteins. UL16 is an envelope glycoprotein, which interferes with the 
immune response by inter action with MICB (MHC Class I-Related chains) 
ULBPs (UL16-binding proteins). 
The critical functions of UL16 and pp65 in viral life cycle encouraged us to study 
these proteins and their roles in viral assembly, membrane and raft association, 
and their interaction with UL97 viral kinase in infected HF cells. Further more, 
the influence of cellular kinase inhibitors, wortmannin and polymyxin B, was 
tested in infected cells.  
Our immunofluorescence experiments using UL16 polyclonal antibodies, 
revealed that UL16 distributed differently in AD169 (wt) infected HF cells, 
compared with ΔUL97 deletion mutant infected cells. UL16 distributed as a “bulb 
like” compact juxtnuclear structure in (wt) viruses infected cells and as a “crown 
like”diffuse perinuclear Structure highly punctuated with vacuoles in ΔUL97 
infected cells. UL16 also co-localized with the major assembly site building 
proteins. Inhibitors of cellular kinase PI-3 and C affected the subcellular 
distribution of UL16 in (wt) virus infected cells as well as the resulted viral titer. 
These inhibitors did not result in major effects on UL16 subcellular distribution or 
on the viral titer in Δpp65 or ΔUL97 infected cells. 
Studying the biochemical properties of UL16 and pp65 employing western blot 
techniques indicated that pp65 is a detergent soluble protein; while UL16 is a 
detergent insoluble raft associated protein. 
Finally we conclude that UL16 glycoprotein is a part of the viral cytoplasmic 
assembly site and that it is a raft association protein. pp65 is not a membrane 
associated protein and is subjected to phosphorylation activity target of UL97 
viral kinase. Both proteins play major roles in HCMV life cycle and the 
knowledge gained here contributed to better understanding of both proteins’ roles 
during HCMV infection.  
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3.4.2- The influence of variable cellular kinase inhibitors and activators on 
subcellular distribution of UL16  
The influence of NGIC-I on HCMV infected cells encouraged us to test further cellular 
kinase inhibitors, which may indicate yet unknown roles for cellular kinases in HCMV 
life cycle. We therefore determined the influence of further cellular kinases on the 
subcellular distribution of UL16 and on the cytoplasmic assembly site in general. For this 
wortmannin, a PI-3 kinase inhibitor, Thrombin, a PI-3 kinase activator and Polymyxin B, 
a cellular kinase C inhibitor were employed. First, drugs were tested using drug inhibition 
assay (3.4) and finally subjected to IF.   
 
 Figure 3.8: Drug inhibition/activation assay. Cells were subjected to drug inhibition 
assay using Wortmannin (100nM) and Polymyxin B (250µg/ml) or activation using 
Thrombin (IU/ml) 2h after infection. At 96hpi, cells were subjected to IF using UL16 
pAb and anti-Rabbit Cy2 (green).  
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Figure 3.8 demonstrate that Wortmannin and Polymyxin B caused a clear inhibition 
along with changes in subcellular distribution of UL16 in AD169 infected cells, which is 
similar to the DUL97 infection characteristic. This conversion affected 30-40% of cells 
(estimated by counting 10 fields with ~1000 cells) compared with 70% in case of NGIC-I 
inhibition (Azzeh et al., 2006). Thrombin did not result in any changes in the case of 
AD169, but a partial conversion of the DUL97 characteristic subcellular distribution of 
UL16 in 30% of DUL97 infected cells (estimated by counting 10 fields with ~1000 cells). 
On the other hand, no changes of subcellular distribution of UL16 was detected in both 
Dpp65 and DUL97 infected cells, when inhibited with Polymyxin B or Wortmannin.  
As indicated in figures 3.4-C, 3.5-B and 3.6-B, changes in subcellular distribution of 
UL16 were consistent with changes in WGA Golgi marker. In order to test, if the drugs 
are influencing the WGA subcellular distribution in uninfected cells, the drug inhibition 
assay with infected cells was performed parallel to uninfected cells. Instead of virus 
containing medium, only medium was added to the uninfected cells (see 3.4). Finally, 
cells were subjected to IF using the WGA Golgi marker. 
Figure 3.9 demonstrates that the addition of the drugs in the current concentration (see 
figure 3.8, 3.9) did not affect the uninfected cells, since Golgi typical appearance did not 
alter in drug treated uninfected cells compared with untreated uninfected cells. This result 
is important since it ensures the fact that changes observed in figure 3.8 are a 
consequence of drugs’ influence only on the infected cells. 
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Figure 3.9: Influence of drugs on uninfected cells. Uninfected cells were subjected to 
drug inhibition assay using Wortmannin (100nM) and Polymyxin B (250µg/ml) or 
activation using Thrombin (IU/ml) parallel to the infected cells in figure 3.8. After 96h, 
cells were subjected to IF using WGA-FITC Golgi marker (green). 
 
3.5 Influence of Wortmannin, Polymyxin B and Thrombin on HCMV 
viral load 
The results obtained from drug inhibition assays of Wortmannin, Polymyxin B and 
Thrombin on UL16 reflects a direct or indirect effect of these drugs on the viral assembly 
site. Viral assembly is a part of the viral life cycle and an inhibition or activation of this 
site or any protein involved in building it may also affect the viral yield. For this, plaque 
assay was performed using the supernatants of the drug inhibition assay experiments 
versus supernatant of non inhibited infections. Log 10 of the resulted viral plaque in each 
test was calculated and a diagram was generated in Excel as early discussed in 2.4 (figure 
3.10). The drugs resulted generally in reduction of viral yield compared to untreated 
51 
 
infected cells. This reduction was not very remarkable in DUL97 infected cells. Although 
not visible on the level of viral assembly, Dpp65 was reduced almost one log by 
Wortmannin. The results for ADI69 titer were in agreement with those results observed 
in the IF. AD169 titer was reduced 2 logs when inhibited with Polymyxin B or 
Wortmannin compared to untreated AD169 titer. Interestingly, although used as an 
activator, Thrombin reduced the viral titer of AD169 half a log. The average plaque assay 
results of 3 independent drug inhibition assays and 3 independent plaque assays were 
utilized to generate the results shown in figure 3.10.  
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Figure 3.10: Titration of the viral supernatant of drug treated versus untreated 
cells. At 96hpi viral supernatant was collected prior to IF treatment and subjected to 
plaque assay. Log 10 of viral titer is given on the Y axis, virus type on the X axis. These 
titration results were confirmed in 3 independent experiments. 
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3.6 Membrane association analysis of HCMV viral proteins 
The membrane association of any viral protein dictates its cellular localization and is 
believed to mediate its role in secondary viral envelopment in the cytoplasm. In this work 
membrane and raft association of UL16 glycoprotein and pp65 were tested. 
 
3.6.1 Membrane association of pp65  
Some viral tegument proteins were shown to be raft or membrane associated as in the   
case of vhs in Herpes simplex virus (Lee et al., 2003). To examine the membrane 
association of the pp65, we carried out flotation assays (see 2.5) using CHAPS as a 
detergent and Nycodenz as a density medium. CHAPS is known to float many 
membrane-associated proteins whereas soluble proteins not associated with membranes 
remain in the bottom of the gradient. As demonstrated in figure 3.11, pp65 is not 
membrane associated, since it did not partition in the top of the floatation. The majority 
of pp65 was detected in fractions 7/8-11/12. Although not membrane associated, we 
observed a remarkable difference, in marked contrast to AD169, the phosphorylated 
portion of pp65 in DUL97 infected cells was down-regulated compared to the 
unphosphorylated portion. Therefore, we are now studying the phosphorylation 
properties of pp65 in the absence of UL97. As a positive control, we used the membrane 
associated pp28, since it was shown before to partition in the top of the floatation (Azzeh 
M et al., 2006).  
 
53 
 
 
AD169                                                          DUL97
Total      1/2   3/4   5/6    7/8   9/10  11/12           total   1/ 2   3/4     5/6     7/8   9/10   11/12    
CHAPS  Floatati on      Top                      bot om                                          top                         bot om
1/2    3/4     5/6    7/8   9/10  11/12                                         1/ 2   3/4    5/6    7/8   9/10  11/12    
pp
65
pp
28
65kDa
28kDa
 
Figure 3.11: Membrane association analysis of pp65. Flotation fraction (numbers 
above) of CHAPS extracts of cells infected with either AD169 or ΔUL97 were collected 
from the top of Nycodenz gradient (1st –low density, 12th –high density) and subjected to 
Western blot analyses using pp65 mAb or pp28mAb.  
 
3.6.2 Raft association of UL16  
As Glycoprotein, UL16 is membrane associated; we therefore checked its rafts 
association. In this case we performed IP after TX-100 floatation, since UL16 was not 
detectable by direct WB. We succeeded to show the 42kDa band of UL16 in fraction 3/4 
at the top of the floatation where the majority of the lower band of double band was clear 
(figure 3.12). For further studying of UL16, we intend though to order a new preparation 
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of the antibody from commercial companies. WB using pp28 was performed as negative 
control, since pp28 is not a raft associated protein (Azzeh et al., 2006).  
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Figure 3.12: Raft association analysis of UL16 protein. Flotation fraction (numbers 
above) of TX-100 extracts of cells infected with AD169 were collected from the top of 
Nycodenze gradient (1st –low density, 12th –high density), Immunoprecipitated with A-
coupled sepharose and UL16 antibody. Finally samples were subjected to Western blot 
analysis using UL16 pAb or pp28 mAb as a negative control.  
 
 
 
CHAPTER 1 
Introduction 
1.1 Herpes Viruses 
1.1.1 Definition 
A typical herpes virion consists of a core, containing a linear double-stranded DNA, an 
icosadeltahedral capsid of approximately 100 to 110 nm in diameter, containing 162 capsomeres 
with a hole running down the long axis. An amorphous-appearing, sometimes asymmetric 
material surrounds the capsid and designated the tegument. There is also an envelope containing 
viral glycoprotein that forms spikes on the viral surface. 
 
1.1.2 Biological Properties 
   The known herpes viruses appear to share four significant biological properties: 
1. All herpes viruses specify a large array of enzymes involved in nucleic acid metabolism, DNA 
synthesis, and processing of proteins. 
2. The synthesis of viral DNAs and capsid assembly occur in the nucleus. 
3. Production of infectious progeny virus is invariably accompanied by the destruction of the 
infected cell. 
4. The herpes viruses examined to date are able to remain latent in their natural hosts. In cells 
harboring latent virus, viral genomes take the form of closed circular molecules, and only a small 
subset of viral genes are expressed. Latent genomes retain the capacity to replicate and cause 
disease upon reactivation. 
 
1.1.3 Classification 
The members of the family Herpesviridae was initially classified into three subfamilies (i.e., the 
Alphaherpesvirinae, the Betaherpesvirinae, and the Gammaherpesvirinae) on the basis of 
biological properties. 
 
1.1.3.1 Alphaherpesvirinae 
The members of the subfamily Alphaherpesvirinae were classified on the basis of a variable host 
range, relatively short reproductive cycle, rapid spread in culture, efficient destruction of infected 
cells, and capacity to establish latent infections primarily but not exclusively in sensory ganglia. 
This subfamily contains the genera Simplex virus (HSV-1, HSV-2), Varicellovirus (VZV), 
Marek's disease-like virus, and Infectious laryngotracheitis-like virus. 
 
1.1.3.2 Betaherpesvirinae 
 A nonexclusive characteristic of the members of the subfamily Betaherpesvirinae is a restricted 
host range. The reproductive cycle is long and the infection progresses slowly in culture. Infected 
cells frequently become enlarged (cytomegalia) and carrier cultures are readily established. The 
virus can be maintained in latent form in secretory glands, lymphoreticular cells, kidneys, and 
other tissues. This subfamily contains the genera Cytomegalovirus (CMV), Muromegalovirus 
(murine cytomegalovirus), Human cytomegalovirus (HCMV) and Roseolovirus (HHV-7). 
 
1.1.3.3 Gammaherpesvirinae 
 The experimental host range of the members of the subfamily Gammaherpesvirinae is limited to 
the family or order to which the natural host belongs. In vitro, all members replicate in 
lymphoblastoid cells, and some also cause lytic infections in some types of epithelioid and 
fibroblastic cells. Viruses in this group are usually specific for either T or B lymphocytes. Latent 
virus is frequently demonstrated in lymphoid tissue. This subfamily contains two genera: 
Lymphocryptovirus (EBV), and Rhadinovirus (AtHV-2 and SaHV-2). 
 
1.1.4 Nomenclature 
The International Committee on the Taxonomy of Viruses (ICTV)-endorsed nomenclature 
consists of designation of herpes viruses by serial Arabic number and the family (most cases) or 
subfamily (for primates and some animals) of the natural host of the virus (e.g., Human herpes 
virus 7, Cercopithecine herpes virus 1). The species number is not intended to imply anything 
about the relationship between a virus and other herpes viruses that infect the same host species 
(e.g., HHV-7 and HHV-8 are members of different subfamilies) or between similarly numbered 
viruses that infect different host species (e.g., EHV-2 and BHV-2 are members of different 
subfamilies). Also, viruses are named according to genes and their products for example, 
glycoprotein B is encoded as UL28 (the position of the gene encoding it) in HSV, U39 in HHV-
6B, UL55 in HCMV, orf8 in HHV-8, and so on.  
 
1.1.5 Cytomegalovirus (CMV) 
This is a distinct, widely distributed subgroup of herpes viruses that share common growth 
characteristics and induce a cytopathology involving characteristic nuclear and cytoplasmic 
inclusions (Smith MG, 1954; Smith MG, 1956; Plummer G, 1973). Viruses in this group were 
generally known as salivary gland viruses until the common name cytomegalovirus was 
proposed by Weller et al. (1960) to reflect both virus-induced cytopathic effects and the virus's 
role in congenitally acquired cytomegalic inclusion disease. 
Cytomegaloviruses are the principal members of the betaherpesvirus subgroup. They share 
several characteristics with other herpes viruses, including virion structure and the ability to 
establish persistent and latent infections. The CMVs exhibit a number of distinguishing 
biological characteristics common to the betaherpesviruses, including salivary gland tropism, 
strict species specificity, and slow growth in cultured cells. 
In most areas of the world, HCMV spreads at an early age and infects the large majority of the 
population. This pattern has been altered by increased hygiene in developed countries, where this 
virus may reach only 40% to 60% of the population. Thus, in the developed world, a large 
proportion of the adult population remains susceptible to primary infection, increasing the risk of 
congenital transmission and subsequent disease. The importance of HCMV as a pathogen has 
also risen over the past three decades with the increase in organ allografting and 
immunosuppressive post transplant therapies and the increase in acquired immunodeficiency 
syndrome (AIDS). These conditions predispose individuals to a primary CMV infection or to 
reactivation of latent infection, which may lead to fulminate, life-threatening disease that can be 
difficult to treat despite the available antiviral drugs (Drew WL and Lalezari JP, 1999; Mocarski 
ES, 1999). 
 
 
 
 
 
1.2 Epidemiology of HCMV Infection 
1.2.1 Distribution, Age, and Demographics 
Seroepidemiologic studies show that HCMV is universally distributed among human populations 
from developed, industrial societies to isolated aboriginal groups (Ahn K et al., 1997; Heise MT 
et al., 1998). Although the prevalence of HCMV infection increases with age in every studied 
group, the overall prevalence of infection and the age at initial acquisition of the virus vary 
greatly according to living circumstances (Bernard N, et al., 2001). In general, prevalence is 
greater and HCMV is acquired earlier in life in developing countries and in the lower 
socioeconomic strata of developed countries. Although in the United States and Europe, HCMV 
infection rates are higher in nonwhites than in whites, racial differences appear to reflect 
differences associated with socioeconomic status and living circumstances (Bernard N, et al., 
2001). Seasonal variation in the incidence of HCMV infection has not been recognized, and 
epidemics have not been described, aside from reports of very high infection rates in institutional 
populations such as day care centers. 
 
1.2.2 Transmission 
Although HCMV is predictably transmitted in settings where susceptible individual have 
frequent contact with body fluids from persons excreting the virus, HCMV is not highly 
contagious and transmission appears to require direct contact with infectious material (Bernard 
N, et al., 2001). Following initial acquisition of HCMV, infectious virus is present in the urine, 
saliva, tears, semen, and cervical secretions for months to years. Not surprisingly, high rates of 
CMV infection occur in settings where close contact with body fluids is expected, such as 
between sex partners, among children in day care centers, and between preschool-aged children 
and their care givers. 
 
1.3 Clinical Features 
1.3.1 CMV Mononucleosis 
It has been estimated that HCMV is responsible for 20% to 50% of heterophile-negative 
mononucleosis and that it accounts for approximately 8% of all cases of mononucleosis (Fons 
MP et al., 1986). As a rule, acquired HCMV infection in the normal host is clinically silent. 
Studies of HCMV infection in pregnant women show that less than 5% of acquired infections are 
symptomatic, and an even smaller percentage are associated with a mononucleosis syndrome 
(Hirai K and Watanabe Y, 1976). Symptomatic infection is also uncommon in infants who 
acquire HCMV during birth or from mother's milk and in preschool-aged children who acquire 
HCMV in day care centers. 
 
1.3.2 CMV Infection in Infants and Children 
Although HCMV is frequently spread from mother to infant during birth or through breast 
feeding, clinical evidence of infection is rare in the healthy, full-term neonate infected 
intrapartum or postnatal from a maternal source. However, among very low birth weight 
premature infants acquired HCMV infection is a significant cause of morbidity.  
Although HCMV infection in infants has been associated with liver disease (Goedhals D et al., 
2008), the risk of disease development is particularly great for newborns with birth weight less 
than 1,500 g who are born to HCMV-seronegative mothers and are infected via receipt of red 
blood cell transfusions from seropositive donors (Lehner PJ et al.,1997). 
 1.3.3 CMV Infection in the Immunocompromised Host 
Cytomegalovirus is one of the most common and difficult opportunistic pathogens that 
complicate the care of immunocompromised patients. Infection is common because it can occur 
(1) by reactivation of latent virus, (2) by reinfection in patients who have had past infection, and 
(3) by primary infection. Procedures that are part of the patient's care, such as transfusions or 
organ transplant, can transmit HCMV at a time when the patient is maximally 
immunosuppressed. HCMV infection in the immunocompromised patient is difficult because 
diagnosis requires not only detection of the virus but also determining whether HCMV is causing 
disease: HCMV shedding and viremia are common in patients with impaired cellular immunity 
even when disease due to HCMV is not present (Bernard N et al., 2001). In addition, preventive 
and therapeutic options are few and not completely effective. The severity of HCMV infection 
roughly parallels the degree of immunosuppression (Garrigue I et al., 2008; Soderberg-Naucler 
C, 2008). 
The most severe infections are seen in recipients of allogeneic bone marrow transplants and in 
patients with acquired immunodeficiency disease (AIDS) with very low CD4 counts. HCMV 
disease is also seen in solid organ transplant patients, in patients receiving immunosuppressive 
chemotherapy for cancer or collagen vascular disease, and in congenital immunodeficiencies. 
Infection is often clinically silent even in the immunocompromised, and when the disease occurs, 
its severity ranges from a brief, self-limited febrile illness to multisystem disease that can be life-
threatening or debilitating. 
 
 
1.3.4 CMV Infection and HIV/AIDS 
Cytomegalovirus infection is important in patients with HIV infection because it is arguably the 
leading opportunistic infection among adults with advanced AIDS. Some investigators have 
found that HCMV infection is associated with clinical progression of HIV infection. Almost all 
adults and approximately 50% of children with HIV infection have serologic evidence of HCMV 
infection (Mussi-Pinhata MM et al. 1998).  
 
1.4 HCMV Structure  
The virion of HCMV consists of an icosahedral capsid encasing a linear genome, surrounded by 
a tegument or matrix (Wright HT et al., 1964; McGavran MH and Smith MG, 1965) and 
enveloped in a lipid bilayer carrying a large number of virus-encoded glycoprotein’s (Spaete RR 
et al., 1994; Britt WJ and Mach M, 1996). By cryoelectron microscopy, the capsid appears 
similar to, though larger than, the herpes simplex virus (HSV)-1 capsid (Chen DH et al., 1999). 
In thin sections of infected cells or by negative staining, the HCMV envelope appears more 
pleiomorphic than the envelope of other herpes viruses (Wright HT et al., 1964), allowing intact 
HCMV virions to be distinguished from other herpes viruses based on morphology. The 
genomes of the characterized HCMVs are all linear DNA molecules ranging in size from 200 to 
240 kbp, which is significantly larger than those of other herpes viruses. 
HCMV infected cells generate three different types of particles including: 
- Infectious mature virions. 
- Non infectious enveloped particles (NIEPs), which is composed of the same viral 
proteins but lack viral DNA. 
- Dense bodies, which are uniquely characteristic of HCMV infection and are non-
replicating, fusion-component enveloped particles, composed primarily of the regiment 
protein pp65. 
The quantities of these different HCMV particles are dependent on the viral strain and the 
multiplicity of infection.  
 
 
Figure 1.1: The Structure of HCMV virus. 
 
1.5 HCMV Virion Proteins 
Purified virus particles of HCMV have been estimated to contain 30 to 40 polypeptides with 
molecular weights ranging in size from 20 to over 300 KD (Gibson W, 1983; Baldick CJ Jr and 
Shenk T, 1996). 
 1.5.1 Capsid Proteins 
The capsid is composed of seven proteins: 
1- Major capsid protein (MCP) is encoded by UL86 and forms both hexons and pentons  
2- Minor capsid protein (mCP) encoded by UL85 
3- Minor capsid binding protein (mC-BP) encoded by UL46  
4- Smallest capsid protein (SCP) encoded by UL48.5 (also called UL48/49)  
5- Three distinct assemblin/assembly protein (AP)-related proteins encoded by UL80, 
UL80a, and UL80.5 associate with capsids (Baldick CJ Jr, Shenk T, 1996; Gibson W, 
1996; Gibson W et al., 1996; Chen DH et al., 1999; Trus BL et al., 1999). Also the 
assemblin/assembly play major roles as scaffolding proteins, which have critical roles in 
capsid assembly. The primary scaffolding components of cytomegalovirus, is the 
assembly protein precursor (pAP, pUL80.5) and the maturational protease precursor 
(pPR, pUL80a), which contains two nuclear localization sequences (NLS1 and NLS2), at 
least one of which is required in co expression experiments to translocate the major 
capsid protein (MCP, pUL85) into the nucleus (Nguyen NL et al., 2008). 
 
 
1.5.2 Envelope Glycoproteins 
The envelope of HCMV contains viral proteins embedded in a host lipid bilayer and is derived 
from intracellular membranes. The acquisition of the envelope and its associated glycoproteins 
occurs at both nuclear and cytoplasmic sites. Envelope glycoproteins are important targets of the 
host antibody-mediated immune clearance mechanisms, and many reviews have been written 
about the synthesis, mapping, function, and immunogenicity of the more prominent envelope 
glycoprotein’s (Mocarski ES, 1993; Britt WJ and Mach M, 1996). Early studies revealed 
approximately eight major glycoprotein species in the human CMV envelope (Gibson W, 1983). 
  
1.5.2.1 gB  glycoprotein  (gpUL55) 
Being recognized as the major envelope constituent, and as the most highly conserved 
glycoprotein in mammalian and avian herpes viruses, gB is a type I integral membrane protein 
that influences virus binding to and entry into cells, cell-to-cell transmission, fusion of adjacent 
cells, and targeting of progeny virus to apical membranes for release from polarized cells 
(Compton T et al., 1993; Navarro D et al., 1993; Bold S, et al., 1996; Tugizov S et al., 1996; 
Tugizov S et al., 1998; Pietropaolo R and Compton T, 1999; Vanarsdall AL et al., 2008). 
Glycoprotein B is the major heparin sulfate proteoglycan-binding glycoprotein, and it binds to a 
30- to 36-kd cellular protein that is a suspected receptor (Adlish JD et al., 1990; Taylor HP and 
Cooper NR, 1990). 
Glycoprotein B is found on all membranes of infected cells and becomes incorporated into 
virions as they undergo envelopment at different sites (Sanchez V et al., 2000). Because it is 
abundant, highly conserved, and the most immunogenic and best-studied envelope glycoprotein, 
gB has been the principle candidate of subunit vaccine initiatives (Spaete RR et al., 1988; Adler 
SP et al., 1999; Pass RF et al., 1999). 
 
1.5.2.2 gH (gpUL75) 
HCMV gH, or gpUL75, is a 742- to 743-amino-acid envelope glycoprotein (Pachl C et al., 
1989), that forms part of a second, relatively abundant glycoprotein complex to which 
neutralizing antibodies may be directed (Rasmussen LE et al., 1984). The gH complexes with at 
least one other herpesvirus-common glycoprotein, denoted gL, facilitates transport to the cell 
surface (Kaye JF et al., 1992; Spaete RR et al., 1993). 
 
1.5.2.3 gL (UL115) 
HCMV gL is encoded by UL115 and is a 278 aminoacid (32-kd) glycoprotein modified by N-
linked and possibly O-linked carbohydrates. Cell-cell fusion is frequently involved in the 
majority of cells.  gB and gH/gL were both necessary and sufficient for fusion, whereas no 
fusion occurred when either glycoprotein was omitted (Vanarsdall AL et al.,2008). 
  
1.5.2.4 UL16 glycoprotein 
The HCMV UL16 gene encodes a glycoprotein that interferes with the immune response to 
virus-infected cell. In vitro, UL16 interacts with MICB (MHC Class I-Related Chains) and 
ULBPs (UL16-Binding Proteins). These proteins are ligands for the stimulatory receptor 
NKG2D, expressed on NK cells and CD8+T cells. UL16 expression has been shown to promote 
intracellular accumulation of MICB, ULBP1and thus, interferes with the immune response to 
HCMV-infected cells (Valés-Gómez  M et al., 2006). 
Several additional viral glycoproteins are likely to be minor envelope constituents but are not 
apparently associated with any major glycoprotein complexes.  
 
1.5.3 Tegument Proteins 
At least 25 proteins are located in the tegument layer between the virion capsid and envelope. 
The products of 11open read frames (ORFs) (UL25, UL26, UL32, UL47, UL48, UL48.5, UL82, 
UL83, UL85, UL88, UL99) have been detected when virion/dense body polypeptides are 
electrophoretically separated. All these proteins appear to be both phosphorylated (Roby C and 
Gibson W,  1986) and highly immunogenic (Landini MP, 1992). These ORFs are all conserved 
in the betaherpesviruses (Nicholas J, 1996; Rawlinson WD et al., 1996; Vink C et al., 2000). 
 
1.5.3.1 pp65 and pp150 
Two tegument proteins, pp150 (ppUL32 or basic phosphoprotein), a 1,048-amino-acid (150 to 
155Kd) protein, (ppUL83 or lower matrix protein), a 561-amino-acid (65 to 68Kd) protein, are 
the most abundant proteins made during replication. 
pp65 is the major tegument protein, and the target antigen in antigenemia assays used for rapid 
diagnosis of HCMV clinical infection. The large amount of pp65 produced by laboratory strains 
of virus is associated with abundant dense body production. Although all tegument proteins are 
phosphorylated, pp65 is a major phosphate acceptor in infected cells. As well it is the primary 
target for phosphorylation in vitro by the virion-associated protein kinase (Somogyi T et al., 
1990). The analysis by mass spectrometry demonstrated that the HCMV tegument aggregates are 
formed principally of the tegument proteins pp65 and ppUL25 but also contained additional 
virion structural proteins including the major capsid protein (Prichard MN et al., 2005). 
Immunoblotting experiments confirmed that the formation of the tegument aggregates appeared 
to be dependent on pp65, since it was not induced in cells infected with a recombinant virus with 
this open reading frame deleted (Prichard MN et al., 2005). 
The other major tegument phosphoprotein, pp150, is the product of UL32 (Jahn G, et al., 1987). 
It is incorporated preferentially into virions rather than dense bodies. It is estimated to make up 
20% of the virion mass (Benko DM et al., 1988). pp150 is a prominent betaherpesvirus-
conserved virion tegument protein, that accumulates within a cytoplasmic inclusion adjacent to 
the nucleus at late times during infection (AuCoin D P et al., 2006).  
 
1.5.3.2 UL97 kinase 
This is a protein kinase encoded by HCMV. It is an important target for antiviral drugs (Kamil JP 
and Coen DM, 2007). Studies of HCMV UL97 kinase deletion mutant (ΔUL97) indicated a 
multi-step role for this kinase in early and late phases of the viral life cycle, namely, in DNA 
replication, capsid maturation and nuclear egress (Wolf et al., 2001). The absence of UL97 
kinase activity results in a modified subcellular distribution of the viral structural protein 
assembly sites, from compact structures impacting upon the nucleus to diffuse perinuclear 
structures punctuated by large vacuoles (Azzeh M et al., 2006). Also UL97 protein has activities 
similar to cellular cyclin-cyclin-dependent kinase (CDK) complexes (Sanchez et al. 2004; Hume 
AJ et al., 2008). UL97 phosphorylate and inactivate the retinoblastoma tumor suppressor, 
stimulated cell cycle progression in mammalian cells, and rescued proliferation of 
Saccharomyces cerevisiae lacking CDK activity (Hume AJ et al., 2008). UL97 is not inhibited 
by the CDK inhibitor p21 and lacks amino acid residues conserved in the CDKs that permit the 
attenuation of the kinase activity (Hamirally S et al., 2009). Thus, UL97 represents a functional 
ortholog of cellular CDKs that is independent of normal CDK control mechanisms (Hume AJ et 
al., 2008).  UL97 kinase plays an important role in the acquisition of tegument during virion 
morphogenesis in the nucleus. This activity represents an important step in the production of 
mature virus particles (Prichard MN et al., 2005).  
Recombinant HCMV that does not express UL97 kinase activity exhibit a distinctive plaque 
morphology characterized by the formation of highly refractile bodies late in infection. These 
structures were also observed in infected cells treated with the UL97 kinase inhibitor maribavir 
(Prichard MN et al., 2005).  
 Both UL97 kinase activity and the LxCxE RB (retinoblastoma pocket proteins) binding motif 
are required for the phosphorylation and stabilization of RB in infected cells. This effect can be 
antagonized by the antiviral drug maribavir (Prichard MN et al., 2008). 
 
1.5.3.3 pp28 (ppUL99) 
The (HCMV) UL99 open reading frame encodes a 190aminoacid myristoylated and 
phosphorylated tegument protein, pp28, that is. pp28 is essential for the assembly of infectious 
virus. Nonenveloped virions accumulate in the cytoplasm of cells infected with recombinant 
viruses with a UL99 deletion. pp28 is localized to the endoplasmic reticulum-Golgi intermediate 
compartment (ERGIC) in transfected cells, while in infected cells, it is localized together with 
other virion proteins in a juxtanuclear compartment termed the assembly compartment (AC) (Seo  
J Y and  Britt W J, 2006).  
 
1.5.3.4 Other HCMV tegument proteins 
The tegument also contains a number of functionally uncharacterized proteins. A virion 
associated protein implicated in genome encapsidation is pp130 (ppUL56) (Bogner E et al., 
1993; Bradshaw PA et al., 1994). Based on drug resistance studies, it was proposed that pp130 
may complex with the CMV terminase (ppUL89) to package viral DNA during virion maturation 
(Krosky PM et al., 1998). One additional protein, pp67, which includes some UL65 sequence 
(Davis MG and Huang ES, 1985), has not been consistently observed in characterized virus 
strains. The association of other tegument proteins encoded by UL25, UL26, UL47, and UL88 
products with the tegument has been determined by sequencing proteins directly isolated from 
virus particles. 
 
 
1.5.4 The Interaction Between pp65 and UL97 
A recombinant HCMV, NTAP97, which expresses a tandem affinity purification (TAP) tag at 
the amino terminus of UL97, was used to obtain UL97 protein complexes from infected cells. 
pp65, the 65-kDa virion tegument phosphoprotein, specifically co purified with UL97 during 
TAP, as shown by mass spectrometry and Western blot analyses (Kamil JP and Coen DM, 
2007). Reciprocal coimmunoprecipitation experiments using lysates of infected cells also 
indicated an interaction between UL97 and pp65. Moreover, in a glutathione S-transferase (GST) 
pull-down experiment, purified GST-pp65 fusion protein specifically bound in vitro-translated 
UL97, suggesting that UL97 and pp65 do not require other viral proteins to form a complex 
(Kamil JP and Coen DM, 2007). Notably, pp65 has been previously reported to form unusual 
aggregates during viral replication when UL97 is pharmacologically inhibited or genetically 
ablated, A pp65 deletion mutant (Δpp65) was observed to exhibit modest resistance to a UL97 
inhibitor (Prichard MN et al., 2005). 
    A stable protein-protein interaction between pp65 and UL97 may be relevant to the 
incorporation of these proteins into HCMV particles during virion morphogenesis. This might 
have  potential implications for immunomodulation by HCMV, and may also be a mechanism by 
which UL97 is negatively regulated during HCMV replication (Kamil JP and Coen DM, 2007).  
Morphologically similar aggregates could be reproduced in nuclei of uninfected cells by over 
expressing pp65. Their formation was prevented by co-expressing the UL97 kinase.  Inhibition 
of UL97 kinase activity with maribavir or mutation of an essential amino acid in the kinase 
abolished its ability to prevent this aggregate formation (Prichard MN et al., 2005). 
 
1.6 The interaction between HCMV and cellular kinases 
HCMV "ensures" that the cellular machinery efficiently supports viral reproduction by 
reprogramming the cellular factors, such as regulatory protein kinases towards virus-specific 
regulatory pathways (Fortunato EA et al., 2000;Bain M and Sinlair J, 2007). Few examples of 
interaction between HCMV and cellular kinases are documented. HCMV infection stimulates 
PI(3)K (Phosphatidylinositol 3-Kinase) activities, and this important for HCMV to usurps PI(3)K 
signal transduction pathways to induce the unique polarization of HCMV-infected monocytes 
needed for the earliest steps in the viral dissemination and persistence strategy (Chan G et 
al.,2009). Also the same with protein kinase C, when endothelial cells were treated prior to 
infection with phorbol myristoyl acetate, an activator of protein kinase C, the number of HCMV-
positive cells increased two to three times. On the other hand, pretreatment of the cells with RO 
31-8220, a specific protein kinase C inhibitor, or with staurosporine, a general protein kinase 
inhibitor, resulted in a decreased infection level (Slobbe-van Drunen ME et al., 1997). The 
activities of CDKs 1, 2, 7 and 9 are crucial for HCMV replication (Bresnahan W A et al., 1997; 
Chen Z et al., 2001; Sanchez V et al., 2001; Sanchez V et al., 2003; Sanchez V and Spector DH, 
2006; Kapasi AJ and Spector DH, 2008; Hamirally S et al., 2009; Rechter S et al., 2009). In the 
course of infection, they phosphorylate the tegument protein pUL69 (Rechter S et al., 2009) and 
mediate phosphorylation of the tegument protein pp65 (Sanchez V et al., 2007). On the other 
hand, the tyrosine kinase affects virus/cell fusion (Keay S and Baldwin BR, 1996). HCMV 
utilize the PI3 kinase pathway to inhibit apoptosis (Yu Y, and Alwine JC, 2002) and to induce 
viral replication (Johnson RA et al., 2001).  
 
1.7 General Considerations in HCMV Growth and Lifecycle  
Human CMV exhibits a highly restricted host range in cell culture. Primary differentiated human 
fibroblasts (HFs) from skin or lung show the greatest susceptibility to viral infection. During 
natural infection, fibroblastic, epithelial, macrophage, smooth muscle, and endothelial cell types 
support productive replication (Sinzger C et al., 1995). Although HFs are commonly used to 
isolate and propagate HCMV in culture, studies have clearly shown that freshly isolated  HCMV 
replicates preferentially on endothelial cell types (Waldman WJ et al., 1991; Woodroffe SB et 
al., 1997; Sinzger C et al., 1999; Riegler S et al., 2000). Undifferentiated, transformed, or 
aneuploid human cells, including almost all cell lines, are nonpermissive (LaFemina RL and 
Hayward GS, 1988). The host cell restriction to HCMV replication observed in nonpermissive 
cells is the result of a postpenetration blockage of viral gene expression and not to a failure to 
enter cells; virus has never been adapted to replicate in any completely nonpermissive cell type. 
HCMV replication in an intestinal epithelial cell line (CaCo-2) has been associated with this host 
cell’s undifferentiated state (Esclatine A et al., 2000). Certain astrocytoma cell lines, such as 
U373MG, although fully permissive (Duclos H et al., 1989), do not support viral replication to 
the high levels observed with fibroblasts. HFs that have been immortalized with the human 
papillomavirus type 16 E6/E7 genes are just as permissive as primary HFs (Compton T, 1993; 
Greaves RF et al., 1995), and such cells have proved to be invaluable as a basis for the 
construction of complementing cell lines for the isolation of viral mutants (Mocarski ES et al., 
1996; Greaves RF and Mocarski ES, 1998). 
 
Attachment and penetration at the cell surface (Compton T et al., 1992) is rapid and efficient in 
permissive as well as in nonpermissive cell types, suggesting that cellular receptors for CMV are 
widely distributed. Addition of exogenous heparin, or treatment of cells with heparinase, blocks 
viral attachment and implicates the major role of cell surface proteoglycan heparan sulfate in the 
initial interaction between virus and cell (Kimpton CP et al., 1989; Neyts J et al., 1992), as is the 
case for other herpes viruses. Initial interaction with heparan sulfate is followed quickly by 
heparin-independent adsorption and penetration steps that employ widely distributed but poorly 
characterized receptors (Adlish JD et al., 1990). The efficiency of penetration depends on the 
presence of these receptors (Nowlin DM et al., 1991; Sinzger C et al., 2008). Initial interest in a 
30- to 36-kd gB-binding cell surface protein that appeared to be annexin II, has been tempered 
by the observation that annexin II does not have to be present on cells for entry. Interest in a gH-
binding phosphoprotein which may be important in penetration (Keay S and Baldwin B, 1991), 
has led to the partial cloning of a CMV fusion A receptor (CMVFR) (Baldwin BR et al., 2000; 
Compton T, 2004) although its full characterization remains to be completed. 
A number of mechanisms for entry have been proposed for cellular and viral functions that may 
influence the efficiency of entry into cells. Heparan sulfate proteoglycan, annexin II, and CD13 
(amino peptidase N) are reported to be associated with HCMV entry into human fibroblast cell. 
Also epidermal growth factor receptor (EGFR) serves as a receptor for HCMV (Compton T, 
2004). 
Attachment to the cell surface is followed by penetration, mediated by fusion of the virion 
envelope and the cell surface in a pH-independent manner, a process that probably involves the 
gH/gL complex (Vanarsdall AL et al., 2008). Viral nucleocapsids rapidly make their way to the 
nucleus. The tegument protein ppUL83 can be detected within 20 to 30 minutes following 
exposure to a virus inoculum, and expression of ie1/ie2 gene products follows shortly thereafter 
(Dal Monte P et al., 1996). Several studies have shown that CMV (or CMV glycoprotein) 
binding to cells is sufficient to initiate a signaling cascade even in the absence of viral 
penetration (Boldogh I et al., 1991; Yurochko AD et al., 1997; Zhu H et al., 1997; Boyle KA, et 
al., 1999; Nguyen NL et al., 2008). Viral attachment may therefore stimulate specific cellular 
processes that facilitate viral replication, or they might be part of some other host cell response to 
viral infection. Low-speed centrifugation (centrifugal enhancement) increases the efficiency of 
adsorption and penetration of murine or human CMV (Woods GL et al., 1987; Agha SA et al., 
1988) by stabilizing weak interactions or encouraging fusion. Productive replication in 
permissive HFs follows a pattern of coordinate expression with viral genes assigned to different 
kinetic classes depending on time of expression and sensitivity to inhibition of protein synthesis 
or viral DNA synthesis. 
Although the replication cycle of HCMV is slow, requiring 48 to 72 hours to begin the release of 
progeny (Stinski MF, 1983), virion tegument proteins influence this earliest phase of infection, 
and viral functions expressed early play regulatory roles later in infection (Kamil JP and Coen 
DM, 2007). The switch from early phase to late phase is delayed until 24 to 36 hours post 
infection (hpi), with maximal levels of virus release starting 72 to 96 hpi. Once maturation starts, 
infected fibroblasts continue to produce the virus at peak levels for several days. 
During productive infection in HFs, a gradual increase in HCMV DNA synthesis is observed 
starting as early as 14 to 16 hpi, and is accompanied by a stimulation of host cell metabolism. 
Viral replication and maturation parallel accumulation of viral DNA replication functions, 
features suggesting that the prolonged replication cycle of this virus may result from this slow 
accumulation of essential gene products. HCMV infection does not inhibit general cellular 
metabolism but rather stimulates both RNA and protein synthesis (Bain M and Sinclair J, 2007; 
Sanchez V and Spector DH, 2008). 
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CHAPTER 2 
2. Materials and Methods 
2.1 Cell line and Cell Culture  
Human foreskin fibroblasts (HF) are a primary cell line isolated from new born male’s foreskin. 
Passage 7 of HF cells was kindly provided by Dr. Nina Mayorek, Hebrew University and 
cultured in culture flasks (Easy Flask, 25 cm2, 75 cm2, 175 cm2, Nunc, Denmark) in complete 
DMEM medium. Complete DMEM medium contains DMEM (01-055-1A, Beit Haemek), 100 
units/ml Penicillin+100µg/ml Streptomycin mixture (03-031-5C, Beit Haemek), 20mM L-
Glutamine (03-020-1A, Beit Haemek) and 10% heat inactivated serum (1:1 mixture of New born 
bovine serum, 04-121-1A and Fetal bovine serum, 04-122-1A, Beit Haemek). Cells were 
cultivated in 96% humid 5% CO2 incubator at 37oC (Hera cell incubator).  
 
2.1.1 Propagation and Passage of HF Cells  
HF cells were propagated by splitting into 2 or more culture flasks, or into different well plates. 
For this, culturing complete medium was removed from confluent cells in flask and replaced 
with 0.25% Trypsin-EDTA (03-052-1A, Beit Haemek). 1 ml was used for trypsinization of 
confluent cells grown on 25 cm2 flask, 2 ml for confluent cells on 75 cm2 flask and 4 ml for 
confluent cells 175 cm2 flask respectively. After 2 minutes incubation, complete medium was 
added to the non adhering trypsinized cells, gently mixed and distributed to the new flasks. The 
new cells are one passage higher than the one they were split from. Since HF is a primary cell 
line, it was propagated up to passage 18 in our lab. Experiments were performed on passages 10-
18.    
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2.1.2 Freezing and Thawing of HF Cells  
Cells can be kept for years if frozen in liquid nitrogen. HF cells were frozen at low passages (6-
12).  Freezing medium (50% complete medium, 40% serum, 10% DMSO, dimethyl sulphoxide, 
Sigma, D2650) is required to keep the cells well maintained while freezing and able to grow 
once thawed. Freezing proceeded as followed: 
For a medium flask, 75cm2  
1- The medium was removed  
2- 2 ml 0.25% Trypsin was added 
3- 6 ml complete medium was added to the detached cells in Trypsin and mixed well 
4- Mixture was equally distributed into 2x 15mL tubes  
5- Tubes were centrifuged at 1500 rpm for 10 min  
6-  The supernatant was discarded carefully 
7-  Pellet in each tube was gently resuspended in 1.5 ml freezing medium  
8- Resuspended cells were transferred into cryotube (Simport, Canada)  
9- Cells in cryotubes were first frozen at -70oC and transferred a day later to liquid nitrogen 
(slow freezing).  
 
For thawing, cells in cryotubes were thawed rapidly and transferred to 25 cm2 culture flasks 
containing 5ml complete media. After 24 hours, complete media was replaced with new 
complete media to remove DMSO residuals. Cells are usually ready to split and passage 48 hours 
after thawing. 
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2.2 Viruses 
HCMV strain AD169 (wt-HCMV; American Type Culture Collection) and pp65 deletion mutant 
(Dpp65) were a kind gift from Prof. Bodo Plachter (Institute of Virology, University Medical Center 
of the Johannes Gutenberg-University, Mainz, Germany). The UL97 deletion mutant, ΔUL97, was 
kindly provided by Dr. Mark Prichard (Dept of Pediatrics, University of Alabama school of 
Medicine, Birmingham, Alabama, USA). 
 
2.2.1 Propagation of Viruses 
 Viruses were propagated in human foreskin fibroblast (HF) culture. Initially HF was infected 
with AD169, Dpp65 or DUL97 at low multiplicity of infection (moi). moi represents the number 
of viruses divided by the number of cells. In this work viruses were propagated in 175 cm2 flasks 
(3x107 HF cells). 4 ml viral suspension (virus stock diluted in complete medium) at moi of 0.001 
were added to the cells and incubated in CO2 incubator. 2 h after infection, viral suspension was 
removed and replaced by 30 ml complete medium. The infection period at this stage is referred 
to as post infection (pi). At 10 days pi, viruses were harvested by collecting the 30 ml 
supernatant in a sterile 50 ml tube and replaced with fresh 30 ml complete medium for further 
incubation. Viral harvest was centrifuged for 10 min at 1500 rpm to get rid of cell debris. The 
clear supernatant was transferred to a new 50 ml tube, 1% DMSO was added, the mixture was 
finally aliquoted in cryotubes and frozen at -70oC. At 14 days pi, a viral re-harvest is performed 
as above and the highly infected cells were discarded.  
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2.2.2 Viral Titration and Plaque Assay 
Plaque assay technique was employed to determine the viral titer (viral count/ml). An aliquot of 
frozen viral harvest (see 2.2.1) was thawed and viral dilutions of 10-1-10-8 (titrations) were 
prepared step wise (1:10 dilution steps) in complete medium. 90-100% confluent HF cells 
cultured in 24 well plates (Nunc, Denmark) were infected with 0.2 ml of either the undiluted 
viral stock, or one of the 10-1-10-8 viral dilutions. The dilutions depend on the virus; wild type 
virus AD169 demands higher dilutions than deletion mutants. Four wells in each column of the 
24 well plate were infected with the same viral dilution, so that 4 controls of each dilution were 
guaranteed.  
Meanwhile, 2.5% agarose was dissolved in sterile dH2O (distilled water) and cooled down to 
50°C. Complete medium was also pre-warmed up to 50°C. 2h after infection, viral media were 
removed from each of the 4 wells in one column and replaced with 1 ml 0.25% agarose 
containing complete medium (2.5% agarose diluted in the pre-warmed complete medium). The 
same is repeated for the rest of the wells in each column. This procedure has to be done pretty 
fast to avoid polymerization of the agarose. Finally, plates are left at room temperature (RT) for 
30 min to allow agarose to polymerize and then transferred to the cell culture incubator. One 
week later, another 1 ml agarose-containing medium is added following the procedure above. 
The agarose in the medium should hinder virus progeny from spreading to neighboring cells and 
allows counting the plaques in the correct dilutions resulting from the infection independently. 
At 2 weeks pi, viral plaques are counted in those wells with those viral dilutions, which allow 
counting separate plaques. Those wells, where viral dilutions used allow counting of 1-20 
plaques are usually chosen to determine viral titer.    
The viral titer, also referred to as plaque forming unit (pfu) was calculated as followed: 
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No. of plaques X Dilution factor X 5 = viruses/ml 
Factor 5 is to calculate the amount /ml, since only 0.2 ml viruses were added to each well, 
multiplication by 5 gives the amount per 1ml. 
 i.e. 10 plaques were counted in dilution 10-5, then there are 10X105 X5 = 5X106 viruses/ml 
 
2.3 Immunofluorescence (IF) 
Cells grown on 8-well glass slides (Labtek chamber slide w/cover, #177402, Nalge Nunc 
International, Naperville, IL 60563) were infected at a (moi) of 0.5 pfu/cell. Supernatant was 
removed at 96h pi (unless otherwise indicated). Cells were washed three times with 1X PBS (8g 
NaCl, 0.2g KCl, 1.44g Na2HPO4, 0.24g KH2PO4 in 1000 ml dH2O, pH 7.4) and fixed with 3.7% 
paraformaldehyde (diluted in PBS) for 30 min at RT. After three washes with PBS, cells were 
permeablized with 0.1% Triton X-100 (diluted in PBS) for 1-2 min at RT. Cells were then 
washed for five times with PBS and blocked with 1% bovine serum albumin (BSA, 0175, 
AMRESCO Inc., USA, prepared in PBS) for 60 min at RT. First antibody (see 2.3.1) was diluted 
in 0.5% BSA and incubated with cells for 2 hrs at RT or over night at 4oC. Cells were washed 5 
times with PBS. The last wash was left on cells for 30 min. The secondary antibodies including 
the Golgi marker (see 2.3.1) were diluted at a proper concentration in 0.5% BSA and incubated 
with the cells 30-60 min in the dark by covering the plates with aluminum paper or by placing 
them in a dark room. Before the last wash, the nucleus was stained with 1µg/ml 4′, 6-diamidino-
2-phenylindole, 2HCl (DAPI, 268298, Calbiochem, Germany) for 10 min at RT. Cells were 
washed 5 times with PBS. Finally, cells were covered with mounting anti-fading solution (0.5% 
g n-porpyl gallate; P3130, Sigma, Germany; 100mM Tris pH 9 , 70% glycerol). The wells were 
carefully peeled off, covered with a cover slip (24X50 mm, Menzel-Gläser) and gently pressed to 
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get rid of excessive mounting solution. The edges of both surfaces of the slide and cover slip 4 
were carefully glued with colorless nail polish. 
If co-localization IF is to be performed, first antibodies, secondary antibodies or secondary 
antibody with Golgi marker were added as a mixture to the cells. 
 
2.3.1 Monoclonal, and Polyclonal Antibodies and Fluorescing Markers 
Variable monoclonal and polyclonal antibodies were used in this work to perform the 
immunofluorescence (IF), Western blot (WB) and immunoprecipitation (IP) assays. Primary 
mouse monoclonal antibodies (mAbs) against HCMV pp28 (CA004-100), pp65 (CA003-100), 
and glycoprotein B (gB, CA005-100) were purchased from Virusys Corporation (Sykesville, 
MD, USA). The polyclonal antibody UL16 (pAb UL16) was kindly provided by Mar Valez, 
Dept of Pathology, University of Cambridge, UK. Secondary antibodies, Goat anti Rabbit-Cy2 
(111-225-144), Goat anti Rabbit-Cy5 (111-175-144), Goat anti-Rabbit-HRP (111-035-003), 
Donkey anti-Mouse-Cy2 (715-225-150), Donkey anti-Mouse-Cy5 (715-175-150) were 
purchased from Jackson Immunoresearch (Jackson ImmunoResearch Laboratories, Inc., West 
Grove, PA, USA). Goat anti-Mouse-HRP was kindly provided by Prof. Moshe Kotler, Dept of 
Pathology, Hebrew University, Jerusalem. All secondary antibodies are highly cross-absorbed. 
Golgi marker Wheat germ agglutinin (WGA, L4895) coupled to fluorescein isothiocyanate 
(FITC) was obtained from Sigma (St Louis, Missouri, USA). All antibodies were reconstituted 
according to supplier, aliquoted in 50µl volumes in eppendorf tubes and frozen at -70°C. For 
current use, antibodies were kept in -20°C. 
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2.3.2 Visualizing staining and processing images of IF experiments 
 Olympus BX60 IF microscope was used for all IF experiments. U-MWIB2 mirror unit was used 
to visualize Cy2 staining, U-MWU2 for DAPI and U-MWIY2 for Cy5 staining respectively. Cell 
images were always captured through the 100X lens with Olympus DP71 camera (unless 
otherwise indicated) and “analySIS LS report” software. Precise single cell images were 
captured using the extra focus tool (FS) on the BX60 microscope. Images were processed and 
merged using “Adobe Photoshop” program.         
 
2.4 Drug Inhibition Assay 
To investigate the influence of drugs (i.e. cellular kinase inhibitors or activators) on HCMV life 
cycle, they were added to HCMV infected cells for a 96 hpi. In this work drug inhibition assay 
was performed to detect structural changes in HCMV infected cells caused by the drug using the 
IF technique. For this, cells grown on chamber slides (see 2.3) were infected with HCMV 
(AD169, DUL97 or Dpp65). Two hours after infection, complete medium containing drug in 
appropriate concentration (see 2.4.1) was added to the cells. At 96hpi supernatant was frozen at  
-70°C to perform plaque assay and cells were subjected to IF as in 2.3. 
Frozen supernatants of drug inhibition experiments versus no inhibition were thawed and 
subjected to plaque assay as in 2.2.2. A diagram was used to demonstrate the influence of a drug 
on the viral titer. Log 10 of resulted viral titers were calculated and used in a the diagram as the 
y-axis against the virus type and drug type in the x-axis (see 3.9, page 48). Results shown in 
diagram were replicable in 3 independent experiments.  
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2.4.1 Antiviral drugs, Cellular Kinase Inhibitors and Activators 
The antiviral drug NGIC-I (MBS481500, Calbiochem, Germany) was reconstituted in DMSO at 
5 mM stock solution, aliquoted and frozen at -20°C. NGIC-I was used at 0.5µM final 
concentration (Azzeh et al., 2006) diluted in complete media. Wortmannin, (W1628, Sigma, 
Germany) was reconstituted in DMSO at 10mM stock solution and used at 100 nM final 
concentration (diluted in complete media). Thrombin (Baxter, USA) was delivered as 1000U/ml 
stock solution and used at 1U/ml (diluted in complete media). Polymyxin B sulfate (50mg/ml 
solution, 420413, Calbiocmem, Germany) was used at final concentration of 250 µg/ml (diluted 
in complete media).  
 
2.5-Flotation Assay 
Floatation assay was performed in order to study the membrane or raft association of viral 
proteins investigated in this work. Such biochemical properties are detectable using specific 
detergents, which are known to float membrane or raft associated proteins. Triton® X-100 (TX-
100, 93443, Sigma, Germany) for example is known to float raft associated proteins, since these 
proteins are insoluble in it. On the other hand, CHAPS (C5070, Sigma, Germany), a non-
denaturing zwitterionic detergent floats membrane associated proteins, while soluble proteins 
remain at the bottom of the gradient (Rouvinski et al., 2003, see below for gradient). Floating is 
connected with the technique used to perform this assay. Cells or infected cells are lysed with a 
buffer containing this detergent and subjected to density gradient centrifugation, all under cold 
condition, cellular and viral proteins, which float in the lowest concentration on the top of the 
gradient are considered raft associated proteins if cells are lysed with TX-100 and membrane 
associated if cells are lysed with CHAPS (see figure 2.1).  
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Figure 2.1: Technical Demonstration of Floatation Assay 
 
Practically the floatation assay was performed under cold conditions (ice) as followed: 
1. Four big flasks (3X107 HF cells) were infected with AD169, ΔUL97, Δpp65 or MOCK at low 
moi: 0.15 for 2h at 37°C in 5% CO2 incubator 
2. Virus containing medium was replaced with 30 ml fresh complete medium and incubated at 
37°C in 5% CO2 incubator 
3. At 6 days pi, medium was removed and cells were washed with cold (4-8 °C) PBS (5 ml each 
flask), and a last wash for 10 min at 4ºC.  
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4. 1.5 ml PBS was added to each flask and the cells were scratched down with a rubber 
policeman in 2 pre-cooled sterile eppendorf tube (equal amounts) 
5. Cells in eppendorf tubes were centrifuged for 10 min at 4ºC, 3000rpm. 
6. The supernatant was discarded very carefully in order not to disturb the cells 
7. The pellets of the same mother flask were resuspended in 1210 µl TNE lysis buffer (25 mM 
Tris (pH 7.5), 150 mM NaCl, 5 mM EDTA +1% CHAPS or 1% TX-100) 
8. Cells were incubated 30 min at 4ºC on ice 
9. Lysates were centrifuged 10 min at 4ºC , 3000 rpm 
10. 990 µl of each tube was transferred to a pre-cooled 5 ml Beckman tube 
11. 990 µl 70 % Nycodenz (D2158, Sigma) in TNE was added to each pre-cooled 5 ml Beckman 
tube and mixed gently to avoid bubbles 
12. The gradient was prepared by stalking the Beckman tubes of step 11 with 440 µl of different 
cold Nycodenz concentrations (prepared in TNE buffer) starting with the highest; 25% and 
ending with the lowest; 8%                           
Start    25%     22.5%     20%     18%     15%    12%     8%      end  
 
13. The tubes were centrifuged in swing TSL 28 Beckman rotor in 80K Beckman centrifuge for 
3 h at 4ºC and 55000 rpm without break  
14. 13 eppendorf tubes for each sample were prepared in order to collect the different fractions 
15. 420 µl of each fraction was aliquoted carefully into each tube 
16. The aliquots were frozen at -70ºC  
17. Floating proteins were detected using Western blot assay (see 2.6) 
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2.6-Western Blot (WB) 
WB is a method to detect proteins in a sample using mono- or polyclonal antibodies, which binds 
specifically to this protein/s. In this work BioRad vertical gel electrophoresis system was used 
(165-3302 Mini-PROTEAN 3 Electrophoresis Module, BioRad, CA, USA).   
  
2.6.1- Preparation of the polyacrylamide Gels 
10% Resolving gel for 2 gels:  
- 7.9 ml dH2O  
- 6.7 ml 40% Polyacrylamide (PAA, Beit Haemek) 
- 5 ml 1.5 M Tris pH 8.8. 
- 0.2 ml 10% SDS (in dH2O) 
- 0.2 ml 10% ammonium per sulfate (APS, prepared in dH2O and frozen until use) 
- 8 µl TEMED (N,N,N′,N′-Tetramethylethylenediamine, T9281, Sigma, Germany) 
Solution was loaded bubble free into the casted 1.5 mm casting glass of BioRad set (see above) 
until 2 cm below the fore glass of the set. 
Once polymerized, 5% stacking solution was prepared: 
- 1.4 ml dH2O 
- 0.33 ml 40 % PAA  
- 0.5 ml 1 M Tris (pH 6.8).  
- 0.02 ml 10% SDS 
- 0.02 ml 10% APS  
- 0.002 ml TEMED 
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Mixture was added bubble free until the top of the fore glass of the BioRad casting system and 
1.5 mm comb was placed between the glasses carefully. 
Once polymerized glass plates with gels and combs were casted in BioRad vertical casting 
system, SDS- Running buffer (25 mM Tris base, 220 mM Glycin, 0.1% SDS) was placed 
between the plates and outside them in the tank. Combs were removed carefully and slots were 
inspected and polymerized gel pieces in the slots were removed carefully if found. 
 
2.6.2-Sample Preparation 
1- 30 µl of floatation aliquots (see step 16, 2.5) were aliquoted in new Eppendorf tubes  
2- 10 µl of 4x Lammli buffer (20mM Tris, pH 6.9, 4% SDS, 40% Glycerol, 0.004% Bromphenol 
blue+ freshly added 8.4% β-Mercaptoethanol) was added to each eppendorf tube 
3- Samples were denaturated at 95° C for 10 min and kept on ice  
4- Samples were carefully loaded into slots along with 2 µl pre-stained protein marker (SM0441 
Fermentas, Canada)  
5- Proteins were run at 80 V (constant Ampere) for 30 min then at 130 V until the smallest 
marker’s protein (20kDa) reached the bottom of the gel 
 
2.6.3-Blotting: 
1- 8.5 X 6.5 cm PVDF membrane (1 per gel) and 8.5 X 6.5 cm Whatmann paper (4 per gel, 
580x580mm thick Whatmann) 
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2- PVDF membrane was activated: 5 min incubation methanol followed by washing in dH2O and 
finally well covered in transfer buffer (3g Tris base, 14.4g Glycin, 800ml dH2O and 200 ml 
Methanol).  Whatmann paper was also well covered with transfer buffer 
3- Stacking gel was separated from Resolving gel by cutting 
4- Blot sandwich was prepared as follwoing  
 2whatmann           Membrane          Gel             2whatmann 
5- Blotting 30 min, 17V, constant Ampere in semi dry blotter 
6- Membranes were blocked in 1% skim milk for 30 min at RT (shaking) or over night at 4ºC  
7- Skim milk was replaced by first antibody (see 2.3.2) diluted in PBS and incubated for 2h 
shaking at RT 
8-Membranes were washed 3 times (15 min each) with PBS 
9- Secondary antibody (see 2.3.1) was diluted 1:10000 in PBS 30 min at RT shaking 
10- Membranes were washed 3 times (15 min each) with PBS, last wash was kept until ECL 
reaction was performed (see 2.6.4)  
 
 2.6.4- ECL Reaction 
ECL reaction and developing of the membranes was performed directly at the Legal Medicine 
center of Al-Quds University. Materials needed below were all carried there to.  
1-Two 15 ml tubes (tube A and tube B) were equally filled with 6ml 100mM Tris pH 8.5  
2- 3.3 µl 30% H2O2 were added to tube A 
    60 µl  Luminol (250mM in DMSO, A8511, Sigma, Germany) + 26.6 µl p-coumaric acid 
(90mM in DMSO, C9008, Sigma, Germany) were added to tube B 
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3- Solutions in tubes A+B were added simultaneously to the membranes and hand shaken with 
membranes for 1 min. 
4- Solutions were poured off 
5- Membrane was placed in a Nylon file  
6- In dark room, membranes were covered with X-ray  negative film and casted for 30 seconds to 
5 min  
7- Negative was developed. If signals were strong, a shorter incubation of the membrane with 
negative was performed. If signals were week, a longer incubation was performed and re-
developed 
8-Membranes were sealed in Nylon file and kept in -20°C or directly stripped (see 2.6.5)  
 
2.6.5 Membrane Stripping 
If another protein with another antibody need to be detected, membranes were stripped, which is 
a method used to denaturate already bound antibodies to allow the access and binding of new 
antibodies. For this, the membrane was treated for 5 min with 300mM NaOH (in dH2O) shaking, 
washed 5 times (15 min each) with PBS and re-blocked with 1% skim milk. 
 
2.6.6 Gel Staining 
In order to check proteins directly on the gel, it was stained after blotting with coomassie blue 
staining solution. Gel was destained with destaining buffer until the protein bands were visible.  
Coomassie staining  solution: 0.25 g Coomassie brilliant blue (R250, Sigma, Germany) dissolved 
in 90ml methanol: H2O (1:1 v/v) + 10 ml Glacial acetic acid.  
Destaining buffer: methanol: acetic acid 1:1 
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2.7 Immunoprecipitation (IP) 
Some proteins cannot be directly detected in WB and therefore have to be immune-precipitated 
first before being subjected to WB. This was the case with the UL16 polyclonal antibody (pAb 
UL16). The following steps were performed to immune-precipitate the UL16 in floatation 
fractions: 
1- 1µL pAb UL16 + 99µL PBS were mixed  and added to 50µl protein A-coupled 
Sepharose  
2- The mixture was rocked over night at 4°C using our self constructed machine in Figure 
2.2. This is the step, by which the Ab was coupled to the Sepharose beads 
3- Mixture was washed 3X with 700 µl (each time centrifuged at 3000 rpm for 1 min) 
4-  100 µl of aliquoted floatation fraction was added to the mixture 
5-  The mixture was rocked for 3h at 4°C 
6- The mixture was re-washed as in step 3 
7- 17 µl of 4x lammli + ß-mercaptoethanol (see 2.6.2) were added to the precipitate and 
subjected to the denaturation step for 10 min at 95°C 
8- Supernatant (15µl) was subjected to WB as in 2.6.2  
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CHAPTER 3 
3. Results 
 
3.1 Subcellular distribution of UL16 glycoprotein in WT, DUL97, and Dpp65 
HF infected cells 
HCMV UL16 gene encodes a glycoprotein that interferes with the immune response to the virus-
infected cell, UL16 may be distributed to an unexpected localization within the cytoplasm of 
infected cells to fulfill its function. For this, HF cells grown on 8-well chamber slides were 
MOCK infected, or infected with either AD169 (wild type), ΔUL97 or Δpp65 deletion mutants at 
a MOI of 0.5. At 96 hpi. The cells were stained for UL16 using anti UL16 polyclonal antibody 
followed by Cy-2 conjugated anti Rabbit and analyzed by immunofluorescence. 
As clearly demonstrated in figure 3.1 and 3.2, UL16 distributed similarly to pp28 as compact 
juxtanuclear "bulb" structure in AD169 and in Δpp65 infected HF cells. On the other hand, UL16 
assumed a diffuse perinuclear, vacuoles’ rich, "crown" structure in ΔUL97 deletion mutant 
infected HF cells (figures 3.1, 3.2). Interestingly, these vacuoles, elsewhere referred to as 
aggregates (Prichard M et al., 2006), did not stain for UL16, as was the case for pp28 (figure 3.2, 
Azzeh M et al., 2006).  
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Figure 3.1: Subcellular distribution of UL16 glycoprotein in HCMV infected HF cells.   
HF cells were infected with AD169, ΔUL97 or ΔPP65 at moi of 0.5 and treated as described in 
2.3. UL16 was stained using pAb UL16 (Rabbit) followed by anti-Rabbit Cy2 secondary 
antibody (green staining). Images were captured with Olympus DP11 digital camera.  
 
   
3.2 Correlation between subcellular distribution of UL16 and nuclear 
structure in HF infected cells  
Not only was the subcellular distribution of UL16 very distinguishable in HCMV infected cells, 
but also the nuclear shape. The particular "bulb" structure of UL16 assumed a compact 
distribution in the center of “kidney” shaped nucleus in AD169/DPP65 infected HF cells (figure 
3.2). Over 70% of nuclei in AD169/DPP65 infected cells assumed the “kidney” shape. This 
percentage was determined by counting DAPI stained nuclei in 10 different fields (in ~1000 
cells) under the IF microscope using the 40X lens. On the other hand, the nuclear shape of 
DUL97 infected cells remained oval as in MOCK infected cells, but was enlarged and punctuated 
by vacuoles of different sizes, similar to the cytoplasmic ones. Neither the cytoplasmic vacuoles 
nor the nuclear ones stained for DAPI or UL16 as shown previously for pp28 (Azzeh M et al., 
2006). The nuclei of Dpp65 infected cells did not show any difference to AD169 infected cells.  
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3.3 Co-localization of UL16 glycoprotein with pp28, pp65, gB, and Golgi 
apparatus  
3.3.1 Co-localization of UL16 glycoprotein with pp28, pp65, gB, and Golgi in HF cells 
infected with AD169 
Here we examined whether the disparate UL16 patterns in cells infected with AD169 might 
reflect a different organization of cellular organelles using antibodies against variable HCMV 
proteins and cellular Golgi. Azzeh and Sanchez (Azzeh M et al., 2006; Sanchez V et al., 2000) 
had shown earlier that different HCMV tegument and glycoproteins co-localize to the 
juxtanuclear assembly. Here we examined whether UL16 co-localizes to that same site. At 96hpi, 
HF cells infected with AD169 were stained with UL16 pAb, co-stained with either gB mAb, 
pp28 mAb, pp65 mAb, or WGA-FITC and counterstained with DAPI. Stained cells were 
analyzed by immunofluorescence microscopy. 
 
UL16 pp28 nucleus merge
 
Figure 3.4 -A: Co-localization of UL16 with PP28 in AD169 infected HF cells. HF cells 
were infected with AD169 at moi o.5 and subjected to IF as described in 2.3. Cells were then 
stained with pp28 mAb (mouse) and UL16 pAb (rabbit) followed by anti-mouse Cy5 (red) 
and anti-Rabbit Cy2 (green). DAPI exerts the blue staining of the nucleus. Images were 
captured with Olympus DP11. 
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Figure 3.4-B: Colocalization of UL16 with gB or pp65 in AD169 infected HF cells. 
Infected HF cells were stained with either gB and UL16 or pp65 and UL16 followed by anti-
mouse Cy5 secondary Ab (red staining) and anti-Rabbit Cy2 (UL16 green staining). DAPI 
exerts the blue staining of the nucleus. Images were captured with Olympus DP11. 
 
Figures 3.4 A and B, demonstrate that UL16 co-localized to 90% with pp28, gB and pp65, which 
indicates that UL16 is a part of the assembly site and may play a role in building the assembly 
site. 
A previous study demonstrated that UL16 co-localized with ER and TGN markers (Vales-
Gomez M, et al., 2005). Here we examined its co-localization with Golgi using a lectin Golgi 
marker (FITC-conjugated WGA). WGA lectin binds to clustered terminal N-acetylneurarninic 
acid residues and to N-acetylglucosamine-containing oligosaccharides on proteins (Bhavanandan 
and Katlic, 1979) and decorates distal Golgi cisternae, the trans-Golgi network (Tartakoff and 
Vassalli, 1983; Virtanen et al., 1980). In uninfected fibroblasts, WGA stained perinuclear 
structures that were reminiscent of the classical Golgi organization, but strikingly modified by 
viral infection (Azzeh et al., 2006). First, the WGA staining intensity in AD169 infected cells 
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was stronger than in uninfected fibroblasts. Most interestingly, the WGA pattern assumed either 
“bulb” or “crown” shapes in AD169 or DUL97 infected cells accordingly with tegument protein 
pp28 ( Azzeh M, et al., 2006).  
Our experiments demonstrate that the glycoprotein UL16 distributes similar to subcellular 
distribution of pp28 and FITC-conjugated WGA, which means that UL16 glycoprotein may play 
a role in inducing a profound reorganization of WGA-positive structure (figure 3.4-C). 
 
UL16WGA nucleus merge
 
Figure 3.4-C: Co-localization of UL16 with WGA in AD169 infected HF cells. HF cells 
infected with AD169 were stained with UL16, followed by a mixture of anti-Rabbit Cy5 
antibody (red staining of UL16) and FITC-conjugated WGA (green). DAPI exerts the blue 
staining of the nucleus. Images were captured with Olympus DP11. 
 
3.3.2  Co-localization of UL16 glycoprotein with pp28, WGA in ΔUL97 infected 
 HF cells   
The effect of the deletion mutant of UL97 on UL16 distribution, viral assembly, and the 
organization of infected cells’ organelles was investigated. For this, HF cells infected with 
DUL97 were stained with UL16 pAb and co-stained with either pp28 mAb or WGA-FITC, and 
analyzed by IF (figure 3.5 A and B).  
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Figure 3.5 A : Colocalization of UL16 glycoprotein with pp28 in HF cells infected with 
DUL97. HF cells were infected DUL97 at moi of 0.5 and subjected to IF (see 2.3). Cells were 
co-stained with UL16 pAb and pp28 mAb, followed by the secondary antibodies anti-Rabbit 
Cy2 (green) and anti-Mouse Cy5 (red). DAPI exerts the blue staining of the nucleus. Images 
were captured with Olympus DP11. 
 
UL16WGA nucleus merge
 
Figure 3.5 B : Colocalization of UL16 glycoprotein with Golgi in HF cells infected with 
DUL97. HF cells were infected DUL97 at moi of 0.5 and subjected to IF (see 2.3). Cells were 
stained with UL16 pAb followed by secondary antibody anti-Rabbit Cy5 (red) and WGA-
FITC (green). Nucleus was counter-stained with DAPI. DAPI exerts the blue staining of the 
nucleus. Images were captured with Olympus DP11. 
 
UL16 glycoprotein co-localized to 90% with pp28 and WGA Golgi marker at the assembly site 
in ΔUL97 cells. These results indicate that the lack of the UL97 kinase does not affect the 
distribution of UL16 or its co-localization with pp28 or Golgi.  
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3.3.3 Co-localization of UL16 glycoprotein with pp28 and Golgi in HF cells infected with 
ΔPP65  
The impact of pp65 deletion on subcellular distribution of variable HCMV proteins is not well 
studies yet. Here we studied the influence of pp65 on UL16, pp28 and Golgi. 
  
 
Figure 3.6 A/B : Colocalization of UL16 glycoprotein with pp28/Golgi in HF cells 
infected with Dpp65. HF cells were infected DUL97 at moi of 0.5 and subjected to IF (3.2). 
Cells were co-stained with UL16 pAb and pp28 mAb in A and only with UL16 pAb in B. 
Secondary antibodies anti-Rabbit Cy2 (green) and anti-Mouse Cy5 (red) were added in A, 
anti-Rabbit Cy5 (red) and WGA-FITC (green) in B. Nucleus DAPI exerts the blue staining of 
the nucleus. Images were captured with Olympus DP11. 
 
UL16 glycoprotein co-localized with pp28 and WGA Golgi marker at the assembly site in Δpp65 
infected cells (figures 3.6 A and B).  
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3.4 Influence of cellular kinases on subcellular distribution of UL16 
HCMV UL97 kinase has several functions in early and late phases of the viral life cycle, namely, 
in DNA replication, capsid maturation, nuclear virion morphogenesis and egress (Azzeh et al., 
2006, Wolf et al., 2000). Here we studied the effect of variable cellular kinases on UL16 
subcellular distribution, cytoplasmic assembly site and viral growth.  
 
3.4.1- The influence of NGIC-I inhibitor on subcellular distribution of UL16 
Indolocarbazole NGIC-I, an inhibitor of cellular protein kinases C, A and G, was shown to 
specifically inhibit the kinase activity of the UL97 in vitro, (Marschall et al., 2001, Azzeh M, et 
al., 2006). We employed this inhibitor to detect the possibility of an effect on UL16 subcellular 
distribution. 0.5μM NGIC-I was added to cells grown on chamber slides 2h post infection with 
either AD169, Dpp65, DUL97 or MOCK (empty vector) infected. At 96hpi IF was performed 
with UL16 pAb. Figure 3.7 shows a conversion of the “bulb” like subcellular distribution of 
UL16 in AD169/Dpp65 infected cells into the ΔUL97 characteristic “crown” like, punctuated 
with vacuoles. In addition, the nuclei lost the typical kidney shape to assume a more oval shape, 
which includes vacuoles as well. By contrast, NGIC-I exerted no additional effects on either the 
UL16 subcellular distribution or the nuclear shape in cells infected with ΔUL97. Taken together, 
these results strongly suggest that it is the lack of UL97 kinase activity that causes the abnormal 
UL16 pattern in cells infected with ΔUL97 (Figure 3.7). 
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CHAPTER 4 
4. Discussion 
The glycoprotein encoded by the HCMV UL16 gene has been shown to be involved in 
the escape of the virus-infected cells from attack by the immune system. Specifically, 
expression of UL16 leads to the accumulation of ligands for the activating receptor 
NKG2D inside the cell. The mechanism, by which this process is driven, is still unknown 
(Vales-Gomez M, et al., 2005). Here, we further investigated the cellular interaction and 
biochemical properties of UL16 in order to understand the role of this glycoprotein in 
HCMV assembly and viral exit, particularly its possible, yet not studied raft association.  
pp65 is a well studied HCMV tegument protein, because of its interaction with variable 
HCMV proteins, cellular proteins, as well as the fact that its abundancy is utilized in 
several experiments for vaccination (Schleiss M R et al., 2007).  UL97 is the only kinase 
encoded by the HCMV and plays a major role in the efficiency of viral replication 
(Prichard MN et al., 1999).  
 
4.1 Subcellular distribution of UL16 in HCMV infected HF cells  
 In AD169 (wt) infected HF cells UL16 distributed as compact juxtnuclear structure 
(figure 3.1). In ΔUL97 infected cells,  UL16 distributed as diffuse perinuclear, vacuoles 
rich structure (figure 3.1), also the nuclear shape changed from typical kidney shape in 
ADI69 infected cells to oval enlarged shape punctuated by vacuoles (figure 3.2). The fact 
that UL16 staining in Dpp65 infected cells behaved similarly to AD169 was not exactly 
expected, since pp65 is an abundant tegument protein that plays variable function in viral 
 56 
life cycle. These results though prove that pp65 does not play a role in building the 
assembly site, nor does it affect its structure. It is also a further proof for the unique effect 
of UL97 on infected cells, since only the UL97 deletion mutant resulted in the “crown” 
like distribution of tegument and glycoproteins. On the other hand, UL97 plays a major 
role in nuclear egress, which seems to be responsible for the invagination of the nucleus 
leading to the kidney shape of the nucleus as assessed in few studies (Prichard et al., 
2005; Azzeh et al. 2006, Das et al., 2007). Our results provide a further evidence for the 
critical role of UL97 kinase in nuclear egress and its visible impact on nuclear shape as 
clearly demonstrated in figures 3.2 and 3.3. This is in agreement with the previous studies 
(Prichard et al., 2005; Azzeh et al. 2006, Das et al., 2007) and the very recent finding of 
Hamirally S et al. (2009).   
 
 
4.2 UL16 glycoprotein co-localized to pp65, gB, pp28, and WGA in both wt-HCMV 
and UL97 deletion mutant 
The results of the subcellular distribution of UL16 obtained gave a hint of strong 
relationship of the UL16 with the viral assembly site, elsewhere referred to as assembly 
complex. Therefore we studied the role of UL16 glycoprotein in the cytoplasmic 
assembly process and the late step of viral maturation. This was approached using IF co-
localization experiments of UL16 with early (pp65) and late viral proteins (pp28 and gB) 
and a Golgi marker. All these viral proteins contribute to the viral assembly site (Sanchez 
V et al., 2000; Azzeh M, et al., 2006).  
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UL16 glycoprotein co-localized to the major viral assembly site building proteins in both 
AD169 and UL97 deletion mutant (figure 3.4 A, B, C and 3.5 A). Also viral infection 
induced a profound reorganization of WGA-positive structure. We found that UL16 
glycoprotein co-localized with these cellular structures (figure 3.5 B). These results 
indicate that UL16 is a part of the HCMV cytoplasmic assembly process and late steps of 
viral maturation. Since UL16 is a part of a viral assembly site and its intracellular 
localization with Golgi was clear, we propose that UL16 plays a major role in the viral 
cytoplasmic assembly pathway. 
 
Our data provides the first evidence for UL16 role in HCMV viral assembly, but also its 
possible direct interaction with the HCMV protein kinase, the UL97. This important 
finding is a first step towards understanding the mechanism(s) of interaction of the UL16 
protein with other viral proteins and possibly HCMV maturation process.  
 
 
4.3 Inhibition of UL97 kinase with NGIC-I resulted in changes of the subcellular 
distribution of UL16 glycoprotein. 
Our observations show that the deletion mutant of UL97 resulted in an abnormal 
distribution of UL16 glycoprotein in HF infected cells (figure 3.1). In order to see if this 
effect is due to the lack of the kinase activity of the UL97 gene product, we employed the 
indolocarbzole NGIC-I, shown to inhibit the kinase activity of the UL97 in vitro 
(Marschall et al., 2001). 
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Treatment of wt-HCMV- infected HF cells with NGIC-I converted the UL16 distribution 
from the typical “bulb like” compact juxtnuclear structure to “crown like” diffuse 
perinuclear Structure highly punctuated with vacuoles (figure 4.7). In addition, the nuclei 
lost the typical kidney shape to assume a more round, regular shape. By contrast, NGIC-I 
exerted no additional effect on either the UL16 subcellular distribution or the nuclear 
shape in the cells infected with ΔUL97. Taken together, these results strongly suggest 
that it is the lack of UL97 kinase activity that causes the abnormal UL16 pattern in cells 
infected with ΔUL97. 
 
We conclude that UL97 kinase play a major role in HCMV life cycle late steps through 
phosphoryaltion, which is in agreement with Kamil J P and Coen D M (2007). This also 
leads to the conclusion that UL16 is indirectly affected by the activity of UL97. We 
propose that protein-protein interaction between UL16 and UL97 kinase take place 
during late infection. This conclusion has to be further investigated and would add a new 
impact to the roles of UL97 kinase activity in viral assembly and on the proteins of the 
viral assembly complex.  
 
 
4.4 The structural changes of the HCMV assembly site are not only affected by the 
UL97 kinase, but also different cellular kinases 
Our earlier data strongly suggested that the UL97 kinase activity is essentially required 
for the formation of the compact viral assembly site. In order to find out if other cellular 
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kinases may contribute to the viral assembly complex and viral load. We employed 
cellular kinase inhibitors. The inhibitors selected were Wortmannin, Polymyxin B and the 
activator Thrombin. 
The effect of these inhibitors/activator was tested on cells infected with AD169, Dpp65 or 
DUL97 and the results are discussed for each virus below. 
    
a) wt-HCMV 
wt-HCMV was affected when treated with Wortmannin (phosphatidylinositol 3-kinase 
inhibitor). 30% of the infected cells showed the subcellular distribution of UL16 
glycoprotein known for ΔUL97 infected cells (figure 3.8). At the same time, wt-HCMV 
titer was reduced by 2 logs compared to untreated. Johnson RA et al. (2001) proposed 
that PI3-K mediates HCMV-induced activation of host cell mitogenic pathways, also 
demonstrated later by Lee GC et al., (2006).  Interestingly, the data by Johnson RA et al. 
(2001) provided strong evidence for the importance of PI3-K activation in initiation of 
HCMV viral DNA replication and completion of viral life cycle. Hereby we are the first 
to identify the one possible step in viral life cycle affected by the PI3-K.  
Polymyxin B revealed similar changes in UL16 subcellular distribution to those exerted 
by Wortmannin. The effect of Polymyxin B on HCMV life cycle by itself was not 
reported yet, but one study showed that PKC may facilitate HCMV/cell membrane fusion 
(Keay S and Baldwin B, 1996). 
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Thrombin (PI3-K activator) did not show detectable influence on AD169 assembly site or 
the viral load. The activity of Thrombin does not seem to be inhibiting or activating any 
process in HCMV life cycle, at least in wt-HCMV life cycle. 
 
b) ΔUL97:  
Interestingly nor Wortmannin or Polymyxin B showed any detectable effect on the 
subcellular distribution of UL16 glycoprotein or on the viral titer in HF cells infected 
with ΔUL97. Thrombin, on the other hand induced the wt-HCMV subcellular distribution 
of UL16 glycoprotein in 20% of infected cells. This may be not very significant, but this 
result is in agreement with that revealed in case of Wortmannin inhibition in wt-HCMV 
infected cells. This means that the influence of Thrombin in wt-HCMV was not 
detectable, even if it was there. Another possibility is that a direct or indirect interactor 
with Thrombin may had been activated only when the viral kinase was missing. 
 
C) Dpp65: 
 None of the drugs showed a major effects when cells were infected with Δpp65, but the 
viral load of Dpp65 was slightly affected by the variable inhibition activities of the kinase 
(data not shown).  
Our cellular kinase inhibition assays suggest that cellular kinase may play a role in the 
assembly site pathway or may have a viral protein substrate among proteins of the 
assembly complex. We conclude that the cellular PI3-K, PKC and viral (UL97) kinases 
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are involved in phosphorylation events necessary for building the assembly site. 
Inhibiting any of the above kinase seems to have an impact on the structural distribution 
of the assembly site. The fact that no change was observed when viral infection was 
performed with Δpp65 may indicate a role of pp65 with cellular kinase activity. It is 
worth studying which step of the cascade reaction of these cellular kinases play the major 
role in building the viral assembly site to be more specific.    
 
4.5 pp65 is not a membrane associated protein  
Our results show that pp65 is a soluble protein and not associated with the membrane. 
Although it is an abundant protein, it is not essential for viral replication or infection, but 
some studies proposed its strong connection with UL97 kinase (Prichard M N, et 
al.,2005; Kamil J P and Coen D M, 2007). Interestingly, our data propose that the 
phosphorylation of pp65 is predominantly controlled by the viral UL97 kinase, since the 
phosphorylated portion of pp65 was markedly reduced in DUL97 infected cells. This 
proposal is in agreement with the model suggested by Prichard MN et al. (2005). 
Prichard MN et al. (2005) proposed a model in which the UL97 kinase influences the 
physical properties of pp65 by direct phosphorylation, which is important for the 
assembly and possibly nuclear egress of the nuclear form of the virion particle. A more 
recent study was able to detect a stable protein-protein interaction between pp65 and 
UL97 as revealed by co-IP experiments (Kamil J P and Coen D M, 2007). Kamil J P and 
Coen D M (2007) concluded that the UL97-pp65 interaction may be essential for direct 
localization of pp65 during assembly by UL97 or the other way round. Kamil J P and 
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Coen D M (2007) referred to an unpublished data done at their lab, where they observed 
the phosphorylation of recombinant pp65 by UL97 in vitro. pp65 is required for the 
incorporation of pUL69 and pUL97 into the virus particle and for viral growth in 
macrophages (Chevillotte M et al., 2008).  
 
Our results and those discussed in this section strongly suggest that pp65 interacts with 
UL97 not only for phosphorylation events but also for facilitating essential roles of pp65 
and of UL97 in HCMV viral life cycle.    
 
4.6 UL16 is a lipid raft associated protein  
Lipid rafts are called detergent-insoluble glycolipid-enriched complexes (GEMs) or 
Detergent Resistant Membranes (DRMs). The first appearance of lipid rafts, or lipid 
rafts-like structure, was occasionally observed by cryo-electronic microscopy in 1980s as 
cavity, such as caveolae. The functional roles of lipid rafts include facilitating the 
signaling proteins on and off through forming a liquid ordered phase. Lipid rafts are also 
involved in virus entry and assembly (Luo C et al., 2008). Lipid rafts in Vero E6 cells are 
involved in the entry of severe acute respiratory syndrome coronavirus (SARS-CoV) (Lu 
Y, et al., 2008). Also HIV entry in macrophages is dependent on intact lipid rafts (Carter 
GC, et al., 2009). All these publications indicate the major role of lipid rafts in virus entry 
and assembly. Some HSV proteins were found to be lipid raft associated like UL11 
(Koshizuka T et al., 2007), UL56 (Koshizuka T et al., 2002) and vhs of UL41 (Grace E et 
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al., 2003).  One study demonstrated that glycoprotein B (of HSV) associated with lipid 
rafts during HSV cell entry (Bender FC et al., 2003).  
   
Non of the HCMV proteins was associated with lipid rafts until today, but a single study 
showed that HCMV entry and interferon (IFN) signaling are coordinated processes that 
require cholesterol-rich microdomains (Juckem LK et al., 2008). This study also 
highlights the complexity of innate immune responses at the earliest points in HCMV 
infection. UL16 glycoprotein has be shown to be involved in the escape of virus-infected 
cells from attack by the immune system, the intracellular distribution of UL16 has been 
found to co-localize with WGA and major HCMV proteins, which indicated the critical 
role of this protein in cytoplasmic assembly and maturation of the virus (figure 4.3A, B, 
C). Also UL16 trafficked through the ER, TGN, and inner nuclear membrane and to the 
plasma membrane (Vales-gomez M, et al., 2006). All these biological properties of UL16 
glycoprotein and the its important role in cytoplasmic assembly discussed in this work, 
pointed out its possible association with lipid rafts. As shown in figure 3.12, the 42kDa 
band of UL16 was detectable in fractions ¾, at the top of the flotation. This indicated the 
lipid raft association of UL16. This result is the first evidence for raft association of 
HCMV viral proteins. Whether this raft association of UL16 is necessary to facilitate its 
critical role in the immune response or the viral entry still need to be further studied.  
 
Finally our finding contributed to the understanding of the biochemical properties and 
roles of pp65 tegument protein and UL16 glycoprotein. Based on these data, we have 
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established a new field of investigation for UL16 and pp65 and provided evidence for 
their essential role in viral life cycle. Our UL16 data enlarges the number of viral proteins 
involved in HCMV cytoplasmic assembly. Being a participant of the assembly complex, 
UL16 may have a critical role as an immune interactor, facilitating the viral assembly 
complex. Finally, our data also emphasizes the unique interaction between UL97 and 
pp65, which is essential for the roles of both proteins and their contribution in viral life 
cycle.  
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